Expression of copeptin in hepatorenal syndrome patients

El-Adway, Nousa Mahmoud; Abdel-Aleem, Mahmoud Saad; Habeeb, Hesham Kamal; Zaki, Zaki Mohamed; Abdel-Gelil, Roby Abdel-Aziz

doi:10.21608/mjmr.2025.350711.1878

Expression of copeptin in hepatorenal syndrome patients

Articles in Press

Document Type : Original Article

Authors

¹ Internal Medicine Department, Faculty of Medicine, Minia University

² Internal Medicine Dept.- Faculty of Medicine - Minia University

³ Clinical pathology department, faculty of medicine, Minia university, Minia, Egypt

10.21608/mjmr.2025.350711.1878

Abstract

Background:Hepatorenal syndrome(HRS)refers to the decline in kidney function occurring in individuals with severe chronic liver disease,advanced cirrhosis,or acute liver failure,without any other identifiable causes of kidney failure and it is related to significant morbidity and mortality. Accurate biomarkers are needed to improve diagnosis and management of HRS.

Objective:The aim of this study is to evaluate the value of copeptin as a biomarker in HRS patients.

Patients and Methods:This is a prospective randomized control study that was performed at Minia University Hospital during the period from December 2021 to August 2023.The study included a total of 100 subjects who were classified to:group(I):Included 20 compensated Cirrhosis patients,group (II):Included 30 decompensated Cirrhosis patients,group (III):Included 30 HRS patients which were classified to Two subgroups as:subgroup(III A):Included 15 Type 1 HRS patients(HRS-AKI)and subgroup(III B):Included 15 Type 2 HRS patients(HRS-CKD)and group(IV) Control:Included 20 healthy subjects.All included were subjected to full history taking,clinical examination and laboratory investigations and copeptin were determined.

Results:There were significant differences among all groups in copeptin level,the highest Copeptin level was recorded in HRS-AKI group(14.4±3.8pmol/L)followed with a significant difference by HRS-CKD group(11.3±2.12 pmol/L)followed with a significant difference by compansated C. group (9.78±1.52pmol/L) and decompansated C. group (9.38±2.34pmol/L)and the lowest level of Copeptin was noticed in the control group (6.86±1.16 pmol/L).At the cutoff of 9.97(pmol/L),copeptin had high sensitivity(90%)in prediction of HRS and the specificity wad 83%.

Conclusion:Copeptin could be considered as good and helpful predictor for AKI in HRS patients. So,testing it against clinical diagnostic criteria rather than tissue diagnosis is an important caveat.

Keywords

Main Subjects